Victoria González Lizarraga

• 2021-2025: Dissemination of general concepts of vaccination and driving actualizations to KOLs and Public Health Authorities, for all immunological products, Implement the medical strategy and scientific leadership in the development and execution of the regional medical plan.
• 2021-2024: For the project Nirsevimab Launch (Pre-launch, Launch, and Post-commercialization) Overcome as achievements: Identify and engage with key KOLs. Implement the KOL engagement plan effectively. Alignment of regional scientific societies, KOLs and decision-makers on the need for AIP (Active Immunization Programs) and the value of nirsevimab across all regions.
• 2024-2025: Integration of all immunological products in the pipeline, being also involve in national authorities recommendation, increase confidence in vaccination, reinforce the added value and benefits of vaccines by capitalizing on our products, services and expertise, Promote Sanofi Pasteur as a leader in vaccination in Spain, Efective engagement with KOLs.

- Implement the medical strategy and scientific leadership in the development and execution of the national medical plan, while product launch.

- Ensure compliance with current internal and external regulations, as well as compliance in medical activities.

- Provide updated scientific information to internal and external stakeholders to add value to both patients and customers.

- Involve external stakeholders in the exchange of medical and scientific information for the therapeutic area during interactions, exhibiting excellent scientific and clinical expertise.

- Gathering data and generating knowledge from stakeholder interactions recording insights to improve medical estrategy

- Keep up-to-date with medical and scientific advancements and establish an effective communication plan for new evidence.
- Support clinical development by assisting with real-world studies and identifying opportunities for evidence generation.
- Attend scientific events and activities.

• Scientific support to internal KOLs for key products
• Review and approval of promotional materials
• Local support for Pharmacovigilance

• Promote and strengthen compliance, good practices and working groups to develop spaces of networking between the local governments and the pharmaceutical industry

• Support in research tasks and clinical data collection.